Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022385 | 0.84 | TSHR (0.44) | ALDH1A1NPC1HSD17B10MAPTTP53 | |
| SCHEMBL1249727 | 0.82 | TSHR (0.43) | ALDH1A1NPC1HSD17B10MAPTTP53 | |
| SCHEMBL3333926 | 0.82 | ALDH1A1 (0.50) | ALDH1A1NPC1HSD17B10MAPTTSHR | |
| SCHEMBL1527765 | 0.81 | TSHR (0.42) | ALDH1A1NPC1HSD17B10MAPTTP53 | |
| SCHEMBL3334719 | 0.81 | TSHR (0.42) | ALDH1A1NPC1HSD17B10MAPTTP53 | |
| SCHEMBL1179173 | 0.81 | ALDH1A1 (0.49) | ALDH1A1NPC1HSD17B10MAPTMAPK1 | |
| SCHEMBL9750587 | 0.81 | ILK (0.43) | ALDH1A1NPC1HSD17B10MAPTTP53 | |
| SCHEMBL23538248 | 0.79 | NPSR1 (0.46) | ALDH1A1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL3330523 | 0.79 | ALDH1A1 (0.44) | ALDH1A1NPC1HSD17B10MAPTTP53 | |
| SCHEMBL2825669 | 0.79 | TSHR (0.44) | ALDH1A1NPC1HSD17B10MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522608-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| EP-2857396-B1 | FUSED HETEROCYCLIC COMPOUNDS FOR PEST CONTROL | SUMITOMO CHEMICAL CO (JP) | 2018-11-21 | — | — | EP | disclosed |
| US-9120792-B2 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| EP-2857396-A1 | FUSED HETEROCYCLIC COMPOUND | Sumitomo Chemical Co., Ltd (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20150094329-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| US-8168642-B2 | Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2012-05-01 | — | — | US | disclosed |
| EP-2039686-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN PREPARATION OF MEDICAMENTS FOR TREATING AND PREVENTING ANTIVIRAL DISEASES | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO LTD (CN) | 2012-02-29 | — | — | EP | disclosed |
| US-20100087448-A1 | Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2010-04-08 | — | — | US | disclosed |
| EP-2039686-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN PREPARATION OF MEDICAMENTS FOR TREATING AND PREVENTING ANTIVIRAL DISEASES | Beijing Molecule Science and Technology Co., Ltd. (CN) | 2009-03-25 | — | — | EP | disclosed |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1664063-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026177-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | HRH4, HRH2, HRH3 | ALDH1A1 2523/4885NPC1 2482/4885HSD17B10 1800/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | ALDH1A1 4167/4885NPC1 2311/4885HSD17B10 2842/4885 |
| US-20100087448-A1 | Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases | DPYD, HPRT1, DHX15 | ALDH1A1 424/4885NPC1 349/4885HSD17B10 1354/4885 |
| US-20150094329-A1 | FUSED HETEROCYCLIC COMPOUND | CYC1, H1-0, H1-3 | ALDH1A1 2414/4885NPC1 1880/4885HSD17B10 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.